Multi-Component Drug Delivery of Paclitaxel
Abstract
Co-delivery systems have been proved to be of much benefit to the anti-cancer drug field. In order to make these drugs successful, nano-particles usage has been promoted. The mini-review has brought forward some of the most prominent co-delivery developments in the field, especially with paclitaxel. The discussion here is never meant to be comprehensive, but to give some new trends and highlights within this area.
Keywords:
Drug Delivery, Nanomedicine, Co-delivery, Paclitaxel
Downloads
Download data is not yet available.
References
1. Dai W, Wang X, Song G, Liu T, He B, Zhang H, et al. Combination antitumor therapy with targeted dual-nanomedicines. Advanced Drug Delivery Reviews. 2017,
2. Kraft J C, Freeling J P, Wang Z, and Ho R J. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. Journal of pharmaceutical sciences. 2014, 103: 29-52
3. Mussi S V, Silva R C, de Oliveira M C, Lucci C M, de Azevedo R B, and Ferreira L A M. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. European Journal of Pharmaceutical Sciences. 2013, 48: 282-290
4. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. Nano LIFE. 2016, 6: 1642002
5. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery. 2017, 24: 233-242
6. Wan C, Allen T, and Cullis P. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug delivery and translational research. 2014, 4: 74-83
7. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. European Journal of BioMedical Research. 2016, 2: 8-14
8. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. Current Drug Metabolism. 2016, 17: 745-754
9. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research. 2016, 2: 12-18
10. Cheng X. DEVELOPING ORGANIC AND INORGANIC NANOMEDICINE FOR CANCER THERAPY. Journal of Drug Delivery and Therapeutics. 2017, 7: 1-4
11. Lee A L, Wang Y, Cheng H Y, Pervaiz S, and Yang Y Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials. 2009, 30: 919-927
12. Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. Journal of controlled release. 2007, 119: 153-162
13. Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016, 99: 129-137; doi: 10.1016/j.addr.2016.01.022.
14. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. 2016, 4: e2140
15. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. Journal of Drug Targeting. 2017, 25: 140-148
16. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. Biochemical and Biophysical Research Communications. 2017, 482: 1201-1206
17. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park T G, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA–PCL–PDMAEMA triblock copolymers. Biomaterials. 2010, 31: 2408-2416
18. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cellular Physiology and Biochemistry. 2016, 40: 443-452
19. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 34: 310-320; doi: 10.1007/s11095-016-2063-5.
20. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as ‘interaction of system to system’and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. Molecular and Cellular Endocrinology. 2016, 434: 219-237
21. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. Journal of pharmaceutical and biomedical analysis. 2016, 129: 514-534
22. Wang H, Zhao Y, Wu Y, Hu Y-l, Nan K, Nie G, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011, 32: 8281-8290
23. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
24. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
25. Patel N R, Rathi A, Mongayt D, and Torchilin V P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. International journal of pharmaceutics. 2011, 416: 296-299
26. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. Chinese Pharmacological Bulletin. 2016: 1433-1441
27. Yu Y H, Kim E, Park D E, Shim G, Lee S, Kim Y B, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. European Journal of Pharmaceutics and Biopharmaceutics. 2012, 80: 268-273
28. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 121-127
29. Guo X K, Sun H P, Shen S, Sun Y, Xie F L, Tao L, et al. Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III. Chemistry & biodiversity. 2013, 10: 73-85
30. Sun H, Zhu J, Chen Y, Sun Y, Zhi H, Li H, et al. Docking Study and Threeâ€Dimensional Quantitative Structureâ€Activity Relationship (3Dâ€QSAR) Analyses and Novel Molecular Design of a Series of 4â€Aminoquinazolines as Inhibitors of Aurora B Kinase. Chinese Journal of Chemistry. 2011, 29: 1785-1799
31. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016, 4: e2757
32. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. Journal of Controlled Release. 2016, 243: 160-171
33. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 2016, 6: 1642007
34. Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. European Journal of BioMedical Research. 2017, 2: 7-11
35. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. Journal of Organic & Inorganic Chemistry. 2016,
36. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. Drug Development Research. 2016, 77: 393-399
37. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 2016, 6: 1642004
2. Kraft J C, Freeling J P, Wang Z, and Ho R J. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. Journal of pharmaceutical sciences. 2014, 103: 29-52
3. Mussi S V, Silva R C, de Oliveira M C, Lucci C M, de Azevedo R B, and Ferreira L A M. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. European Journal of Pharmaceutical Sciences. 2013, 48: 282-290
4. Liu F, Sun Y, Kang C, and Zhu H. Pegylated Drug Delivery Systems: From Design to Biomedical Applications. Nano LIFE. 2016, 6: 1642002
5. Qiao H, Fang D, Chen J, Sun Y, Kang C, Di L, et al. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery. 2017, 24: 233-242
6. Wan C, Allen T, and Cullis P. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug delivery and translational research. 2014, 4: 74-83
7. Kang C, Sun Y, Wang M, and Cheng X. Nanosized camptothecin conjugates for single and combined drug delivery. European Journal of BioMedical Research. 2016, 2: 8-14
8. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of Nanoparticles for Treatment of Brain Tumor. Current Drug Metabolism. 2016, 17: 745-754
9. Sun Y, Kang C, Zhang A, Liu F, Hu J, Zhong X, et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research. 2016, 2: 12-18
10. Cheng X. DEVELOPING ORGANIC AND INORGANIC NANOMEDICINE FOR CANCER THERAPY. Journal of Drug Delivery and Therapeutics. 2017, 7: 1-4
11. Lee A L, Wang Y, Cheng H Y, Pervaiz S, and Yang Y Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials. 2009, 30: 919-927
12. Zhang L, Yang M, Wang Q, Li Y, Guo R, Jiang X, et al. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. Journal of controlled release. 2007, 119: 153-162
13. Cheng X, and Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016, 99: 129-137; doi: 10.1016/j.addr.2016.01.022.
14. Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T, et al. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ. 2016, 4: e2140
15. Han R, Sun Y, Kang C, Sun H, and Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. Journal of Drug Targeting. 2017, 25: 140-148
16. Kang C, Qin J, Osei W, and Hu K. Regulation of protein kinase C-epsilon and its age-dependence. Biochemical and Biophysical Research Communications. 2017, 482: 1201-1206
17. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park T G, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA–PCL–PDMAEMA triblock copolymers. Biomaterials. 2010, 31: 2408-2416
18. Song L, Kang C, Sun Y, Huang W, Liu W, and Qian Z. Crocetin Inhibits Lipopolysaccharide-Induced Inflammatory Response in Human Umbilical Vein Endothelial Cells. Cellular Physiology and Biochemistry. 2016, 40: 443-452
19. Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017, 34: 310-320; doi: 10.1007/s11095-016-2063-5.
20. Duan Y, Pei K, Cai H, Tu S, Cheng X, Zhang Z, et al. Strategy of integrated evaluation on treatment of traditional Chinese medicine as ‘interaction of system to system’and establishment of novel fuzzy target contribution recognition with herb-pairs, a case study on Astragali Radix-Fructus Corni. Molecular and Cellular Endocrinology. 2016, 434: 219-237
21. Duan Y, Pei K, Cai H, Tu S, Zhang Z, Cheng X, et al. Bioactivity evaluation-based ultra high-performance liquid chromatography coupled with electrospray ionization tandem quadrupole-time-of-flight mass spectrometry and novel distinction of multi-subchemome compatibility recognition strategy with Astragali Radix-Fructus Corni herb-pair as a case study. Journal of pharmaceutical and biomedical analysis. 2016, 129: 514-534
22. Wang H, Zhao Y, Wu Y, Hu Y-l, Nan K, Nie G, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011, 32: 8281-8290
23. Li H, Cheng X, Liu Y, Lee Y B, Kim D J, Ahn C-h, et al. Folate receptor-targeted lipid coated albumin nanoparticles (F-LCAN) for therapeutic delivery of RX-0201 (Archexin®), an antisense oligonucleotide against Akt-1. 2016,
24. Li H, Quan J, Zhang M, Yung B C, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1alpha. Mol Pharm. 2016, 13: 2555-2562; doi: 10.1021/acs.molpharmaceut.6b00363.
25. Patel N R, Rathi A, Mongayt D, and Torchilin V P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. International journal of pharmaceutics. 2011, 416: 296-299
26. XU S-h, Chen K, CHEN M-l, ZHOU P-p, HE G-w, CUI Y-j, et al. Dynamic expression of AQP4 in early stageof ischemia/reperfusion rats and cerebral edema. Chinese Pharmacological Bulletin. 2016: 1433-1441
27. Yu Y H, Kim E, Park D E, Shim G, Lee S, Kim Y B, et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. European Journal of Pharmaceutics and Biopharmaceutics. 2012, 80: 268-273
28. Waller A P, George M, Kalyanasundaram A, Kang C, Periasamy M, Hu K, et al. GLUT12 functions as a basal and insulin-independent glucose transporter in the heart. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013, 1832: 121-127
29. Guo X K, Sun H P, Shen S, Sun Y, Xie F L, Tao L, et al. Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III. Chemistry & biodiversity. 2013, 10: 73-85
30. Sun H, Zhu J, Chen Y, Sun Y, Zhi H, Li H, et al. Docking Study and Threeâ€Dimensional Quantitative Structureâ€Activity Relationship (3Dâ€QSAR) Analyses and Novel Molecular Design of a Series of 4â€Aminoquinazolines as Inhibitors of Aurora B Kinase. Chinese Journal of Chemistry. 2011, 29: 1785-1799
31. Xue X, Zhao N-Y, Yu H-T, Sun Y, Kang C, Huang Q-B, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel–Lindau interaction through shape-based screening and cascade docking. PeerJ. 2016, 4: e2757
32. Yang Z, Xie J, Zhu J, Kang C, Chiang C, Wang X, et al. Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation. Journal of Controlled Release. 2016, 243: 160-171
33. Yao Z, Sun Y, and Kang C. Structure and Self-Assembly of Multicolored Naphthalene Diimides Semiconductor. Nano LIFE. 2016, 6: 1642007
34. Zhong X, Sun Y, Kang C, and Wan G. The theory of dielectrophoresis and its applications on medical and materials research. European Journal of BioMedical Research. 2017, 2: 7-11
35. Sun Y, and Kang C. Self-Assembly of Peptides into Hydrogel. Journal of Organic & Inorganic Chemistry. 2016,
36. Sun Y, Kang C, Liu F, and Song L. Delivery of Antipsychotics with Nanoparticles. Drug Development Research. 2016, 77: 393-399
37. Sun Y, Kang C, Yao Z, Liu F, and Zhou Y. Peptide-Based Ligand for Active Delivery of Liposomal Doxorubicin. Nano LIFE. 2016, 6: 1642004
Statistics
314 Views | 410 Downloads
How to Cite
1.
Zhang Z. Multi-Component Drug Delivery of Paclitaxel. JDDT [Internet]. 14May2017 [cited 29Mar.2024];7(3):80-3. Available from: https://jddtonline.info/index.php/jddt/article/view/1451
Section
Mini Review
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).